| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 14.28 | 0.53 (+3.85%) | 6.62 - 14.77 | 1.3 million |
Market data as of 4:00PM 05/17/13. Quotes are delayed by at least 15 min.
| Open | 13.82 |
|---|---|
| Previous Close | 13.75 |
| Day's Range | 13.74 - 14.34 |
| Market Cap | 1.3B |
| Avg Volume (10 Day) | 1.4M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.19 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Pass |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Fail |
| Increased shareholder value? | Fail |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Pass |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Pass |
| Has sufficient liquidity? | Pass |
NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Year® 2013
Business Wire - Thursday 05/16/2013 8:00 AM ET
NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for Gattex® as an Innovative Treatment for Patients with Short Bowel Syndrome
Business Wire - Wednesday 05/15/2013 8:15 AM ET
NPS Pharmaceuticals Reports First Quarter 2013 Financial Results
Business Wire - Thursday 05/09/2013 8:00 AM ET
NPS Pharmaceuticals to Report First Quarter 2013 Financial Results
Business Wire - Wednesday 05/01/2013 8:00 AM ET
NPS Pharmaceuticals Among 100 Best Places to Work in New Jersey for Second Consecutive Year
Business Wire - Friday 04/26/2013 8:00 AM ET
NPS Pharmaceuticals to Present at Needham Healthcare Conference
Business Wire - Monday 04/22/2013 8:10 AM ET
| NPSP | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 31.84% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 10.10 |
| Company | Last | Change |
|---|---|---|
| 6.75 | -7.66% | |
| Acorda Therapeutics Inc | 32.94 | +1.26% |
| Immunogen Inc | 16.29 | +1.31% |
| Santarus Inc | 21.91 | +3.01% |
| VIVUS Inc | 12.30 | -1.91% |
Data is delayed by at least 15 min.